A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Safety and Dose-ranging Study of Three Oral Doses (0.5 mg, 2.5 mg and 10 mg Once Daily) of TCH346 in Patients With Amyotrophic Lateral Sclerosis.
TCH346 represents a potential advancement in the treatment landscape for Amyotrophic Lateral Sclerosis (ALS), a disease with significant unmet medical need and limited therapeutic options. The study's completion indicates Novartis Pharmaceuticals' commitment to addressing ALS, which could enhance its portfolio in neurology. The competitive landscape includes existing therapies such as Riluzole and Edaravone, but TCH346's unique dosing regimen and mechanism may provide a differentiated offering. Market diligence should focus on the efficacy and safety outcomes from this trial, as well as the potential for further development and commercialization strategies, including partnerships or licensing opportunities.
Indication: Amyotrophic Lateral Sclerosis
Modality: small molecule
Target: TCH346 is a novel compound with a specific mechanism of action yet to be fully elucidated in the context of ALS treatment.
Sponsor: Novartis Pharmaceuticals
Source URL: ClinicalTrials.gov
Source updated: Nov 24, 2011
Ingested: Jun 13, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: TCH346 is a novel compound with a specific mechanism of action yet to be fully elucidated in the context of ALS treatment.
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis
Condition normalized: Amyotrophic Lateral Sclerosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: TCH346 is a novel compound with a specific mechanism of action yet to be fully elucidated in the context of ALS treatment.
Target normalized: TCH346 is a novel compound with a specific mechanism of action yet to be fully elucidated in the context of ALS treatment.